ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
DealStreetAsia

Singapore Hummingbird to start COVID antibody therapy trial

SK-backed startup receives approval from local authorities

 A nurse cares for a COVID-19 patient in the intensive care unit at King Chulalongkorn Memorial Hospital in Bangkok on April 23, 2020.   © Reuters

SINGAPORE -- Cancer antibody developer Hummingbird Bioscience has received approval from Singapore health authorities to start a clinical trial for COVID-19 antibody therapy.

Early trials are ongoing while a Phase 3 trial is scheduled for the end of the year. The latest trial will study the safety and efficacy of the experimental treatment HMBD-115, the company said.

Preclinical studies have shown that HMBD-115 significantly reduced viral loads, attenuated inflammatory responses linked to severe disease and lung damage, and increased survivability, Hummingbird said.

HMBD-115 has also been shown to bind with high potency to all common strains of the coronavirus, including the D614G variant that has become the dominant strain globally.

Hummingbird Bioscience, founded in 2015 in Singapore, uses systems biology to develop an antibody discovery platform that is able to accurately identify key targets within the diseased cells, engineer molecules to hit those targets, and effectively prevent cell proteins from replicating.

It recently raised $25 million in a Series B round led by South Korean conglomerate SK Holdings.

Other shareholders who participated in the round included private equity and venture capital company Heritas Capital and SEEDS Capital, the investment arm of Enterprise Singapore. Previous backers include Mirae Asset Venture Investment and GNTech Venture Capital.

That round brought the total capital that Hummingbird has raised to $65 million.

For the original story from DealStreetAsia, click here.

DealStreetAsia is a financial news site based in Singapore that focuses on private equity, venture capital and corporate investment activity in Asia, especially Southeast Asia, India and Greater China. Nikkei owns a majority stake in the company.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more